Common use of Formation and Composition Clause in Contracts

Formation and Composition. Provided that Immunocore has not issued a Co Funding Withdrawal Notice, within [***], the Parties shall establish a joint commercialization committee (the “JCC”) to develop and agree a commercialization plan throughout the Territory (“Commercialization Plan”) for the Licensed Products and to oversee, review and manage the activities under the Commercialization Plan. The JCC shall be composed of at least [***] but no more than [***] representatives designated by each Party and the Parties need not have the same number of representatives. Representatives must be appropriate for the tasks then being undertaken and the stage of development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JCC contact. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing the other Party’s representatives in writing (which may be by email) in advance and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and JPT Co-Leaders may attend meetings of the JCC but shall have no right to vote on any decisions of the JCC.

Formation and Composition. Provided that Immunocore has not issued a Co Funding Withdrawal Notice, As soon as reasonably possible and in any event within [***]] after the Effective Date, the Parties Immunocore and Lilly shall establish a joint commercialization research committee (the “JCCJRC”) to develop monitor and agree a commercialization plan throughout coordinate the Territory (“Commercialization Plan”) for the Licensed Products communication and to oversee, review and manage the activities of both Parties under the Commercialization PlanResearch Plans. The JCC JRC shall be composed of at least [***] but no more than [***] representatives designated by each Party and the Parties need not have the same in each case an equal number of representativesrepresentatives from each Party. Representatives must be appropriate for the tasks then being undertaken and the stage of developmentresearch or pre-clinical development relevant to any Research Plans, in terms of their seniority, decision-making authority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JCC contactJRC contact (“Project Co-Leader”). Each Party may replace its representatives from time to time by informing upon written notice to the other Party in writing (which may be by email)Party; provided, however, if a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing providing notification in writing to the other Party’s representatives in writing (which may be by email) in advance and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and JPT Co-Leaders may attend meetings of the JCC JRC but shall have no right to vote on any decisions of the JCCJRC.

Formation and Composition. Provided that Immunocore has not issued a Co Funding Withdrawal Notice, As soon as reasonably possible and in any event within [***]] after the Effective Date, the Parties lmmunocore and GNE shall establish a joint commercialization development committee (the “JCCJDC”) to develop and agree a commercialization plan throughout act as the Territory (“Commercialization Plan”) for the Licensed Products and steering committee to oversee, review and manage the activities under development of the Commercialization PlanLicensed Products in accordance with the Development Plans. The JCC JDC shall be composed of at least [***] but no more than [***] representatives designated by each Party (and the Parties need not have the same number of representatives). Representatives must be appropriate for the tasks then being undertaken and the stage of development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JCC JDC contact. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing the other Party’s representatives in writing (which may be by email) in advance and following provision of such written notification the alternate will be entitled to perform the functions of such representative. , The Alliance Managers and JPT Project Co-Leaders may attend meetings of the JCC JDC but shall have no right to vote on any decisions of the JCCJDC.

Formation and Composition. Provided that Immunocore has not issued a Co Funding Withdrawal NoticeFollowing [***], as soon as reasonably possible and in any event within [***]] days thereafter, the Parties shall establish a joint commercialization development committee (the “JCCJDC”) to develop and agree ), which will serve as a commercialization plan throughout the Territory (“Commercialization Plan”) forum for the Licensed Products and exchange of information with respect to oversee, review and manage the activities under Development of the Commercialization PlanCollaboration Off-the-Shelf T-Cell Therapies Directed To each Collaboration Target for which an Opt-In is in effect. The JCC JDC shall be composed of at least [***] but no more than [***] representatives designated by each Party and the Parties need not have the same number of representativesParty. Representatives must be appropriate for the tasks then being undertaken and the stage of development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JCC JDC contact. Each Party may replace its representatives from time to time by informing the other Party Party’s Alliance Manager in writing (which may be by email); provided, however, that if a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing the other Party’s representatives Alliance Manager in writing (which may be by email) in advance and following provision submission of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and JPT Co-Leaders may attend meetings of the JCC but shall have no right to vote on any decisions of the JCCJDC.

Formation and Composition. Provided that Immunocore has not issued a Co Funding Withdrawal Notice, within As soon as reasonably possible after […***…], the Parties Adaptimmune and Bellicum shall establish a joint commercialization development committee (the “JCCJDC”) to develop monitor and agree a commercialization plan throughout coordinate the Territory (“Commercialization Plan”) for the Licensed Products communication and to oversee, review and manage the activities of both Parties under the Commercialization each Co-Development Plan. The JCC JDC shall be composed of at least […***…] but no more than […***…] representatives designated by each Party and the Parties need not have the same in each case an equal number of representativesrepresentatives from each Party. Representatives must be appropriate for the tasks then being undertaken and the applicable stage of research, pre-clinical development or clinical development, in terms of their seniority, decision-making authority, availability, function in their respective organizationsorganisations, training and experience. Each Party shall designate one of its representatives as its primary JCC contact. Each Party may replace its JDC representatives from time to time by informing upon written notice to the Alliance Manager of the other Party in writing (which may be by email)Party; provided, however, if a Party’s JDC representative is unable to attend a JDC meeting, such Party may designate an alternate to attend such JDC meeting by informing providing notification in writing to the other Party’s representatives in writing (which may be by email) in advance Alliance Manager and following provision of such written notification the alternate will be entitled to perform the functions of such representativeJDC representative at such JDC meeting. The Alliance Managers and JPT Co-Leaders may attend meetings of the JCC JDC but shall have no right to vote on any decisions of the JCC.JDC. 132265684 v23 Page 15

Formation and Composition. Provided that Immunocore has not issued As soon as reasonably practicable, Adaptive and GNE shall establish: (a) a Co Funding Withdrawal Noticejoint research committee (the “JRC”) to monitor and coordinate the activities under the Research Program, which the Parties shall form, in any event, within [***], ] days after the Parties shall establish Effective Date; and (b) a joint commercialization development committee (the “JCCJDC”) to develop monitor and agree a commercialization plan throughout the Territory (“Commercialization Plan”) for the Licensed Products and to oversee, review and manage coordinate the activities under the Commercialization PlanDevelopment Program; ((a) and (b), collectively, the “Committees”). The JCC Committees shall each be composed of at least [***] but no more than [***] representatives designated by each Party (and the Parties need not have the same [***] number of representatives). Representatives must be appropriate for the tasks then being undertaken and the stage of developmentresearch or Development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JCC contactJRC or JDC contact on the respective Committee. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, that if a Party’s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing the other Party’s representatives in writing (which may be by email) in advance and following provision submission of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and JPT Co-Leaders may attend meetings of the JCC Committees but shall have no right to vote on any decisions of the JCCa Committee.